Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $13.23 billion. The enterprise value is $13.55 billion.
Important Dates
The last earnings date was Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 61.10 million shares outstanding. The number of shares has increased by 5.57% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.10M |
| Shares Change (YoY) | +5.57% |
| Shares Change (QoQ) | -4.94% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 80.74% |
| Float | 60.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 89.52 |
| PS Ratio | 17.20 |
| Forward PS | 11.21 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03
| Current Ratio | 1.03 |
| Quick Ratio | 0.70 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.99 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -7.69% |
| Return on Invested Capital (ROIC) | -12.99% |
| Return on Capital Employed (ROCE) | -82.18% |
| Revenue Per Employee | $745,912 |
| Profits Per Employee | -$268,740 |
| Employee Count | 1,017 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 0.30 |
Taxes
In the past 12 months, Ascendis Pharma has paid $11.28 million in taxes.
| Income Tax | 11.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.18% in the last 52 weeks. The beta is 0.45, so Ascendis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +71.18% |
| 50-Day Moving Average | 202.09 |
| 200-Day Moving Average | 174.69 |
| Relative Strength Index (RSI) | 63.58 |
| Average Volume (20 Days) | 504,349 |
Short Selling Information
| Short Interest | 3.55M |
| Short Previous Month | 3.42M |
| Short % of Shares Out | 7.05% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.52 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $758.59 million and -$273.31 million in losses. Loss per share was -$4.54.
| Revenue | 758.59M |
| Gross Profit | 658.46M |
| Operating Income | -162.24M |
| Pretax Income | -262.03M |
| Net Income | -273.31M |
| EBITDA | -156.88M |
| EBIT | -162.24M |
| Loss Per Share | -$4.54 |
Full Income StatementBalance Sheet
The company has $632.51 million in cash and $954.65 million in debt, giving a net cash position of -$322.14 million or -$5.27 per share.
| Cash & Cash Equivalents | 632.51M |
| Total Debt | 954.65M |
| Net Cash | -322.14M |
| Net Cash Per Share | -$5.27 |
| Equity (Book Value) | -204.24M |
| Book Value Per Share | -3.34 |
| Working Capital | 36.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$125.16 million and capital expenditures -$6.43 million, giving a free cash flow of -$129.95 million.
| Operating Cash Flow | -125.16M |
| Capital Expenditures | -6.43M |
| Free Cash Flow | -129.95M |
| FCF Per Share | -$2.13 |
Full Cash Flow StatementMargins
Gross margin is 86.80%, with operating and profit margins of -21.39% and -36.03%.
| Gross Margin | 86.80% |
| Operating Margin | -21.39% |
| Pretax Margin | -34.54% |
| Profit Margin | -36.03% |
| EBITDA Margin | -20.68% |
| EBIT Margin | -21.39% |
| FCF Margin | n/a |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.56% |
| Shareholder Yield | -5.56% |
| Earnings Yield | -2.07% |
| FCF Yield | -0.98% |
Dividend DetailsAnalyst Forecast
The average price target for Ascendis Pharma is $245.76, which is 13.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $245.76 |
| Price Target Difference | 13.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 53.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 0.74 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.74 |
| Piotroski F-Score | 4 |
